What it sells
Pharma manufacturing
Business model breakdown
Buyer: who owns the budget?
UnverifiedSite head / operations leaders at CDMOs and integrated pharma GMP sites.
Trigger: what makes them buy now?
Capacity feels maxed out while OEE is typically 45-65% versus 85% world class; need to take on new volumes without new lines.
Workflow: what inputs become what output?
AIM platform: Capacity Finder uncovers idle equipment windows and operator hours, Production Activation turns them into scheduled hours, Production Acceleration recommends recovery paths on deviations.
Economics: what it saves and how it charges
Value claimed as 20% capacity recovered on bottleneck equipment with no added capex, turned into production in under 90 days.
Distribution: how it reaches customers
Direct sales ("Find Capacity Now" CTA) with case studies and events.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-02-09 | — | $1.6M | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.